PDM 11

CAS No. 1032508-03-4

PDM 11( 1-[2-(4-Chloro-phenyl)-vinyl]-35-diMeth )

Catalog No. M20906 CAS No. 1032508-03-4

PDM 11 is an antagonist of aryl hydrocarbon receptor (AhR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 37 In Stock
10MG 33 In Stock
25MG 69 In Stock
50MG 110 In Stock
100MG 176 In Stock
200MG 259 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PDM 11
  • Note
    Research use only, not for human use.
  • Brief Description
    PDM 11 is an antagonist of aryl hydrocarbon receptor (AhR).
  • Description
    PDM 11 is an antagonist of aryl hydrocarbon receptor (AhR).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    1-[2-(4-Chloro-phenyl)-vinyl]-35-diMeth
  • Pathway
    Endocrinology/Hormones
  • Target
    AhR
  • Recptor
    AhR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1032508-03-4
  • Formula Weight
    274.74
  • Molecular Formula
    C16H15ClO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc1cc(/C=C/c2ccc(Cl)cc2)cc(OC)c1
  • Chemical Name
    (E)-1-(4-chlorostyryl)-35-dimethoxybenzene

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.De Medina P Casper R Savouret J F et al. Synthesis and Biological Properties of New Stilbene Derivatives of Resveratrol as New Selective Aryl Hydrocarbon Modulators[J]. Journal of Medicinal Chemistry 2005 48(1):287-291.
molnova catalog
related products
  • Leflunomide

    Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs.

  • KYN-101

    KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity.

  • CAY10464

    CAY10464 (AHR antagonist 7) is a potent AHR antagonist with potential antitumor activity that inhibits CYP1A1 mRNA expression and may be used to study cancer and metabolic diseases.